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Background: Although a combined Haemophilus influenzae type b (Hib)/meningococcal capsular group C (MenC)
conjugate vaccine with a tetanus toxoid carrier protein (Hib/MenC-TT) is not licensed for use in those above 2 years
of age due to lack of data on safety and efficacy, certain patient groups at high risk of MenC and/or Hib disease are
recommended to receive it. Laboratory workers working with Hib and/or MenC cultures may be at a potentially
increased risk of acquiring infectious diseases and vaccination is therefore an important safety consideration. We
undertook a clinical trial to investigate the safety and immunogenicity of Hib/MenC-TT vaccine in this cohort.
Methods: A total of 33 subjects were recruited to the trial, all of whom were vaccinated. Serology was completed
on samples taken at baseline and four weeks following vaccination to determine MenC specific IgG, MenC serum
bactericidal antibody (SBA), anti-Hib polyribosylribitol phosphate (PRP) IgG and anti-tetanus toxoid IgG responses.
Results: At baseline, high proportions of subjects had protective antibody concentrations against MenC, Hib and
tetanus due to previous vaccination and/or natural exposure. Vaccination induced > 3, 10 and 220 fold increases in
geometric mean concentrations for MenC SBA, anti-tetanus toxoid IgG and anti-Hib PRP IgG, respectively. Following
vaccination, 97% of subjects had putative protective SBA titres ≥ 8, 100% had short term protective anti-Hib PRP IgG
concentrations ≥ 0.15 μg/mL and 97% had protective anti-tetanus toxoid concentrations ≥ 0.1 IU/mL. No safety
concerns were reported with minor local reactions being reported by 21% of subjects.
Conclusions: Immunological responses determined in this trial are likely a combination of primary and secondary
responses due to previous vaccination and natural exposure. Subjects were a representative cross-section of
laboratory workers, enabling us to conclude that a single dose of Hib/MenC-TT was safe and immunogenic in
healthy adults providing the evidence that this vaccine may be used for providing protection in an occupational
setting.
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Glycoconjugate vaccines to provide protection against
Haemophilus influenzae type b (Hib) and Neisseria menin-
gitidis capsular group C (MenC) were implemented into
the UK immunisation schedule in 1992 and 1999, respect-
ively [1,2]. The Hib vaccine was extremely effective in the
targeted age group reducing invasive disease in England
and Wales from almost 500 cases per year to 20 cases,
two years following implementation [1]. The MenC vac-
cine was similarly successful and reduced disease inci-
dence by 86.7% in the targeted age groups, also within two
years of implementation [3]. Despite the success of these
vaccines, cases in the UK general population still occur
from which live isolates are initially cultured in local
microbiology laboratories prior to transfer to reference la-
boratories at Public Health England (PHE). Transmission
of Hib and MenC is achieved via the aerosol/respiratory
route and as laboratory staff handle live cultures they can
be considered to have a potential occupational exposure.
Use of live cultures is not restricted to clinical and refer-
ence laboratories as there are many additional laboratories
undertaking research. This results in a significant popula-
tion of laboratory workers with a potential exposure risk
including those undertaking functional immunoassays
such as the MenC and Hib serum bactericidal antibody
(SBA) assay to evaluate vaccine responses.
The potential risk was confirmed in an analysis con-
ducted in the UK which determined laboratory workers to
have a 184-fold increased risk of meningococcal disease
compared to the general population [4]. This supports the
requirement for employers to provide protection wherever
possible to laboratory staff, with a potential occupational
exposure to infectious disease [5]. Protection from acquisi-
tion and disease in the laboratory should primarily rely on
physical control measures, however occupational vaccin-
ation is an important final form of defence. This is
highlighted by a number of reports of potentially vaccine-
preventable meningococcal cases in laboratory staff [6-10].
Occupational vaccination in the UK against meningo-
coccal disease over the last decade has been generally
achieved using monovalent MenC conjugate (MCC), A
and C bivalent polysaccharide and quadrivalent A, C, Y
and W vaccines initially in the form of polysaccharide for-
mulations which have now been superseded by conjugate
products [11]. Vaccination against Hib has been more
problematic as the only available vaccines are combination
vaccines designed for infant immunisation. In 2005, Meni-
torix® a combined Hib/MenC conjugate vaccine with a tet-
anus toxoid (TT) carrier protein was licensed in Europe
and incorporated into the UK immunisation schedule
from September 2006 as a 12 month booster vaccination
[1]. The vaccine is also licensed for primary vaccination in
infants from 2 months up to 12 months of age as a three
dose course given with an interval of at least 1 monthbetween doses. Although not licensed or generally for use
in children above 2 years of age due to lack of data on
safety and efficacy, it is recommended in certain patient
groups to reduce the number of immunisations required
[11]. Children and adults with asplenia or splenic dysfunc-
tion, may have a suboptimal response to MCC vaccine
[12] and are recommended to receive a single dose of
Hib/MenC-TT followed one month later by a single dose
of a quadrivalent meningococcal A, C, Y and W conjugate
vaccine [11].
The availability of Hib/MenC-TT vaccine provided the
opportunity to offer vaccination to laboratory staff who
routinely work with live Hib and/or MenC cultures at the
Manchester Medical Microbiology Partnership (MMMP).
We therefore undertook a clinical trial to evaluate the im-
munogenicity and safety of a single dose of Hib/MenC-TT
vaccine in staff at a potential occupational exposure to Hib
and/or MenC.Methods
Study population and schedule
Enrolment into this single dose Hib/MenC-TT vaccine
trial was open to adult (≥18 years of age) laboratory staff
from the MMMP who were considered to be at potential
occupational exposure to Hib and/or MenC. Potential oc-
cupational exposure was defined as routine handling of
live Hib and/or MenC cultures which included both scien-
tific staff from the PHE Meningococcal Reference Unit
and the Vaccine Evaluation Unit (VEU) and porters/auto-
clave staff. At the time of enrolment this incorporated a
greater range of staff than were at that time required to re-
ceive occupational meningococcal vaccination which was
limited to scientific staff. Inclusion criteria ensured partici-
pants had no contraindications to vaccination as specified
in the “Green Book” [11], written informed consent and
availability for at least the initial trial (vaccination) visit.
To allow the vaccine to be provided to as many laboratory
staff as possible, exclusion criteria were limited to known
or suspected pregnancy.
The non-adjuvanted Hib/MenC-TT vaccine (0.5 mL
dose containing 5 μg of Hib polysaccharide (polyribosylri-
bitol phosphate (PRP)) conjugated to 12.5 μg of TT and
5 μg of MenC polysaccharide conjugated to 5 μg of TT
(GlaxoSmithKline, UK), from a single lot (Batch number
A76CA008A), was administered in the deltoid muscle of
the non-dominant arm. Vaccination was deferred if the
oral temperature measured was >38°C, or if there was
acute illness on the day of vaccination. Blood samples
were taken before and 4 weeks following vaccination. Sub-
jects were asked to provide details of any medication
taken at enrolment and throughout the follow up period
and meningococcal vaccine histories were obtained from
the Occupational Health Department.
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Serum samples were assayed in the VEU, using a multi-
plexed fluorescent bead assay to quantify IgG antibody
concentrations to MenC, Hib PRP and tetanus toxoid,
based upon previously published methodology [13,14].
Functional antibody activity against MenC was deter-
mined in the SBA assay as previously described [15]. The
target strain in the SBA assay was C11 (C:16:P1.7-1,1) and
the complement source was baby rabbit sera (Pel-Freeze
Incorporated, Rodgerson, AZ, USA) (rSBA). rSBA titres
were expressed as the reciprocal of the final serum dilu-
tion giving ≥ 50% killing at 60 minutes. For computational
purposes, rSBA titres lower than the serum starting dilu-
tion of 4 were assigned a value of 2.Correlates of protection
Immune correlates indicative of protection have been
established for Hib, MenC and tetanus [16-18]. Hib PRP
IgG concentrations ≥0.15 μg/mL and ≥ 1.00 μg/mL are
considered the putative short term and long term pro-
tective levels, respectively [17]. For MenC, a rSBA titre
of ≥ 8, four weeks after vaccination was shown to pre-
dict short term clinical protection against MenC disease
in the UK [16] while a rSBA titre ≥ 128 reliably pre-
dicted a SBA titre using human complement of ≥ 4 [19],
the accepted hSBA correlate of protection [20,21]. For
tetanus, anti-toxoid levels < 0.1 IU/mL denote suscepti-
bility and levels ≥ 1.0 IU/mL are considered as providing
long term protection [18,22].Safety
Subjects were monitored for 30 minutes following vac-
cination and then completed a daily health diary for
seven days recording any local reactions (erythema,
swelling, tenderness) and measurements if present. Oral
temperature was also recorded as well as any visits to a
doctor, hospital or general practitioner or any medica-
tion taken. A vaccine research nurse followed up sub-
jects by telephone 24 hours following vaccination to
enquire about any reactions or problems.Figure 1 Participant flow chart.Analyses
At each time point the proportions of subjects achieving
rSBA titres ≥ 8 and ≥ 128, anti-PRP IgG antibody concen-
trations ≥ 0.15 μg/mL and ≥ 1.00 μg/mL and anti-tetanus
toxoid IgG antibody concentrations ≥ 0.10 IU/mL and ≥
1.00 IU/mL were calculated. MenC rSBA geometric mean
titres (GMTs) and MenC-specific IgG, anti-PRP IgG and
anti-tetanus toxoid IgG geometric mean concentrations
(GMCs) with 95% confidence intervals (95% CI) were also
calculated. Due to the small sample sizes, immunogenicity
analysis did not include any formal statistical analysis.Governance
The trial was conducted in accordance with the 1996
International Conference on Harmonisation Good
Clinical Practice (ICH GCP) guidelines, the 2000 Dec-
laration of Helsinki and the 2004 EU Clinical Trial
Directive. A favorable opinion was given by the UK
Medicines and Healthcare products Regulatory Agency
(MHRA) and the National Research Ethics Service,
Northern and Yorkshire Research Ethics Committee.
The EudraCT number was 2006-004302-74 and the trial
was registered on the public website, www.clinicaltrials.
gov under the identifier: NCT00503165.
Results
A total of 35 staff responded to trial advertisements of
which 33 were available for the first visit and were en-
rolled and vaccinated (Figure 1). Women accounted for
61% (20/33) of those enrolled reflecting the higher propor-
tion of women laboratory staff within the eligible recruit-
ment cohort. At enrolment the mean age of subjects was
30 years 2 months (range, 22 years 5 months to 59 years
10 months). Of the 33 subjects vaccinated, blood samples
were obtained for 29 subjects at both time points. Three
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enrolled and vaccinated as the investigators’ principal aim
was to afford potential benefit of vaccination to as many
staff as possible. The trial was undertaken between July
and September 2007 and the mean number of days be-
tween the baseline blood draw/vaccination and blood
draw following vaccination sample was 31 days (range
18–64 days; median 28 days). Telephone follow-up at
24 hours was completed for all participants and diaries
were completed and returned by 29 subjects.Immunogenicity
Prior to vaccination, 79% and 66% of subjects had puta-
tive protective MenC rSBA titres ≥ 8 and at the higher
cut off of ≥ 128, respectively (Table 1). Following vaccin-
ation, a 3 fold increase in MenC rSBA GMT was deter-
mined whilst MenC-specific IgG GMC only increased
1.5 fold (Table 1). Proportions of subjects with rSBA ti-
tres above the two cut offs increased from the initially
high background levels with all but one subject achiev-
ing an rSBA titre ≥ 8 following vaccination (Table 1).
For Hib at baseline, high proportions of subjects (62%)
had anti-PRP IgG ≥ 0.15 μg/mL, the putative short term
protective concentration while a lower proportion (31%)
had putative long term protective concentrations ≥
1.0 μg/mL (Table 1). Following vaccination, a > 200 fold
increase in anti-PRP IgG GMC was determined which
resulted in all subjects achieving anti-PRP concentra-
tions ≥ 0.15 μg/mL and all but one achieving concentra-
tions ≥ 1.0 μg/mL (Table 1).
Anti-tetanus toxoid IgG serology undertaken to deter-
mine responses induced by the carrier protein indicated
a > 10 fold increase in IgG GMC following vaccination
in comparison to baseline levels (Table 2). This resulted
in all but one subject achieving anti-tetanus toxoid IgG
concentrations ≥ 0.10 IU/mL and ≥ 1.0 IU/mL compared
to 90% and 45% at baseline, respectively (Table 2).Table 1 Proportions of subjects with MenC serum bactericida
antibody geometric mean titres with 95% confidence interva
95% confidence intervals, anti-PRP Hib IgG geometric mean c
proportions of subjects with anti-PRP Hib IgG ≥ 0.15/≥1.00 μg
rSBA GMT (95% CI)
N (%) with rSBA titres ≥8
N (%) with rSBA titres ≥128
MenC IgG GMC (95% CI) μg/mL
N (%) with anti-PRP Hib IgG concentrations≥ 0.15 μg/mL
N (%) with anti-PRP Hib IgG concentrations≥ 1.00 μg/mL
Anti-PRP Hib IgG GMC (95% CI) μg/mLSafety
Concomitant medication was reported by 11 (33%) partic-
ipants. Two participants (6%) took over the counter tab-
lets – one took Ibuprofen for an exercise injury on day 0
of the trial, and the other took paracetemol on day 8 of
the trial for a raised temperature and nasal congestion.
Nine participants (27%) took medication for chronic con-
ditions during the trial, which the trial medic assessed as
unrelated to trial treatment.
From the 29 diaries returned, six participants (21%) re-
ported local reactions following vaccination, of which ten-
derness was most frequently reported (Table 3). Five
participants (17%) reported systemic symptoms (Table 3).
Participants reporting hay fever, hypertension and nasal
congestion/raised temperature were medicated as above.
In one participant an episode of dizziness and nausea
commenced approximately 8 hours following vaccination
and subsided after 48 hours. The individuals with hyper-
tension and hay fever consulted their GPs about these
conditions. There were no visits to hospital, or Serious
Adverse Events reported during the trial.Discussion
To our knowledge this trial is the first report of the safety
and immunogenicity of a Hib/MenC-TT combination vac-
cine in healthy adults which to date, has only been ap-
proved for children from 2 months up to 2 years of age.
The vaccine was safe and immunogenic in the trial popu-
lation indicating that it is suitable for use in an occupa-
tional setting to provide protection to laboratory staff
which may have a potential occupational exposure to Hib
and/or MenC.
Investigation of the immunogenicity of the MenC vaccine
component was complicated as trial subjects were labora-
tory workers, who had previously received meningococcal
vaccination. Consequently, 79% of subjects had baseline
MenC rSBA titres ≥ 8 which is at least double, thanl antibody titres ≥8/≥128, MenC serum bactericidal
ls, anti-MenC IgG geometric mean concentration with
oncentration with 95% confidence intervals and
/mL before and following vaccination with Hib/MenC-TT
Baseline Following vaccination
151.2 (52.2 – 437.9) 454.3 (200.9 – 1027.3)
23/29 (79%) 28/29 (97%)
19/29 (66%) 24/29 (83%)
4.3 (2.1 – 8.8) 6.6 (3.3 – 13.1)
18/29 (62%) 29/29 (100%)
9/29 (31%) 28/29 (97%)
0.23 (0.09 – 0.60) 50.69 (24.28 – 105.84)
Table 2 Proportions of subjects with anti-tetanus toxoid IgG antibody concentrations ≥ 0.10/1.0 IU/mL and geometric
mean concentrations with 95% confidence intervals at baseline and following vaccination with Hib/MenC-TT
Baseline Following vaccination
N (%) with anti-tetanus toxoid IgG concentrations≥ 0.10 IU/mL 26/29 (90%) 28/29 (97%)
N (%) with anti-tetanus toxoid IgG concentrations≥ 1.00 IU/mL 13/29 (45%) 28/29 (97%)
Anti-tetanus toxoid GMC (95% CI) IU/mL 0.77 (0.47 – 1.27) 8.20 (4.65 – 14.46)
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of age in 2009 [23]. At enrolment, subjects with prior vac-
cination against MenC had been vaccinated with MCC vac-
cine either through the MCC catch-up campaign during
1999 to 2000 [2], a MCC staff trial [24] and/or through the
Occupational Health Department with multivalent polysac-
charide vaccines. Eight subjects had also received 3 doses of
the “Norwegian” outer membrane vesicle (OMV) vaccine,
MenBvac (Norwegian Institute of Public Health), in a trial
in 2005/6 [25]. The OMV vaccine may have been respon-
sible for elevated baseline rSBA titres due to induction of
cross-reactive antibodies against subcapsular proteins on
the MenC target strain. Of the six staff without putative
protective MenC rSBA titres, three were not required to be
vaccinated by the then current occupational vaccination
program although two had received MCC vaccination
seven years previously. The three other staff had received a
quadrivalent polysaccharide vaccine three years previously
and were two years away from the recommended five year
re-vaccination point [11]. The clinical significance of SBA
titres below the protective level is undetermined as while
SBA titres ≥ than the protective level equate to protection
from disease, a SBA titre < than the protective level does
not necessarily indicate susceptibility [20,21].
Following vaccination, all but one subject achieved
MenC rSBA titres ≥ 8 and the MenC rSBA GMT in-
creased three fold from baseline levels. The rSBA response
was mainly achieved in subjects with low baseline titres as
the average individual fold change in rSBA titre following











Nasal congestion/raised temperature 1/29 (3%)
Hay fever 1/29 (3%)rSBA titres < 128 and ≥ 128, respectively (data not pre-
sented). This is in agreement with previous studies where
negative correlations between baseline antibody concentra-
tions and subsequent booster responses have been reported,
including trials using Hib/MenC-TTas a booster [26].
The phenomenon of immunological hyporesponsive-
ness, characterised by decreased immunological responses
upon repeated doses of MenC containing vaccines after
initial MenC polysaccharide vaccination has been well
documented in both adults [27-30] and younger children
[31-33]. Two previous laboratory staff studies utilising
MCC vaccine also demonstrated hyporesponsiveness in
staff who had previously been vaccinated with meningo-
coccal A and C bivalent polysaccharide vaccine in com-
parison to naïve controls [24,34]. Unfortunately, we were
not able to make the same comparison in our own trial as
all but one of the subjects had previously received menin-
gococcal vaccination. Interestingly, these two trials re-
ported greater increases in rSBA GMT and IgG GMC in
both the naïve and the previously vaccinated groups than
achieved in the trial we report here. It is difficult to deter-
mine the reason for this although the most apparent dif-
ferences were that the previous trials used MCC as
opposed to Hib/MenC-TT and many of the subjects in
our trial had more complex previous meningococcal vac-
cination histories with high baseline immunity against
MenC. In the future, any detrimental impact of prior poly-
saccharide vaccination should hopefully become less of an
issue as meningococcal quadrivalent conjugate vaccines
are now available and are recommended over polysacchar-
ide vaccines for use in at risk-groups [11].
Despite none of the subjects reporting previous vac-
cination against Hib, 62% and 31% of subjects had base-
line anti-Hib PRP IgG levels consistent with short and
long term protection, respectively. These proportions
were similar, although higher than those reported in the
UK general population in 2009, whereby 57% and 21%
of the 25–44 year age group were reported to have short
and long term protective anti-Hib PRP IgG levels, re-
spectively [35]. Following vaccination a > 200 fold rise in
anti-PRP IgG GMC was measured, all subjects achieved
short term protective antibody concentrations and all
but one subject achieved an anti-PRP level ≥ 1.00 μg/mL.
Subjects also had baseline tetanus toxoid IgG levels
similar to that in the UK adult general population in
2009 [36] with 10% and 45% of subjects at baseline and
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tible and long term protective antibody concentrations,
respectively. Following vaccination a >10 fold rise in IgG
GMT was achieved and all but one subject serocon-
verted to achieve IgG levels over 0.1 IU/mL. These data
indicate that immune response to Hib/MenC-TT was
not restricted to the two polysaccharide antigens and
that the carrier protein is also able to induce a robust
immune response in primed adults. Similar findings have
previously been reported in meningococcal conjugate
vaccines trials [37,38] and is an important finding as la-
boratory workers are also recommended to receive ap-
propriate tetanus vaccination [11]. The ability of Hib/
MenC-TT to boost tetanus antibody concentrations may
negate the need to use an additional specific tetanus
containing vaccine. This is of particular benefit as the
unavailability of a monovalent tetanus vaccine in Europe,
requires the use of a combination vaccine (Revaxis®,
Sanofi Pasteur MSD) which in laboratory workers poten-
tially unnecessarily contains diphtheria and inactivated
poliovirus antigens.
Following Hib/MenC-TT, it was three different individ-
uals who failed to achieve protective antibody levels against
MenC, Hib and tetanus indicating that this was not due to
a single individual/vaccination. Overall, the vaccine was
well tolerated with a maximum of 21% of subjects reporting
any systemic or local reactions of which they were generally
minor and of short duration. This reactogenicity profile, is
similar to that which would be predicted from previous
Hib/MenC-TT trials undertaken in pediatric populations
[39]. Unfortunately, it is not possible to compare reacto-
genicity to the one trial completed in older children as no
safety data were reported [40].
Conclusions
In conclusion, Hib/MenC-TT when administered as a
single dose to healthy adults is safe and immunogenic.
Due to subject’s previous meningococcal and tetanus
vaccination in combination with probable natural ex-
posure, immunological responses were likely to be a
combination of primary and secondary responses. These
are however, a representative sample of laboratory
workers/healthy adults and therefore, provide evidence
that this vaccine may be used in the occupational setting
for providing protection against MenC and/or Hib. The
vaccine also induced a robust response against the car-
rier protein, indicating that the vaccine can also boost
protection against tetanus. The importance of these
findings relates to the unavailability of monovalent con-
jugate Hib vaccines in Europe, necessitating the use of
multivalent products of which Hib/MenC-TT has the
lowest valency. These data reported here from healthy
adults may also provide an insight into the immunogen-
icity and safety of Hib/MenC-TT in other at-riskpopulations, thus supporting the UK vaccination policy
for vaccinating asplenic and hyposlpenic individuals [11].
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